Article info

Download PDFPDF

Original research
Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus

Authors

  1. Correspondence to Professor Yoshiya Tanaka; tanaka{at}med.uoeh-u.ac.jp
View Full Text

Citation

Tanaka Y, Kumanogoh A, Atsumi T, et al
Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus

Publication history

  • Received June 28, 2024
  • Accepted August 26, 2024
  • First published September 17, 2024.
Online issue publication 
September 17, 2024
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.